23:21 , Jan 9, 2018 |  BC Extra  |  Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
17:57 , May 16, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Tumor levels of eight proteins could help predict survival in melanoma. In patients, low tumor levels of eight tumor suppressors -- tumor necrosis factor α-induced protein 3 (TNFAIP3; A20), PR domain containing...
21:37 , May 5, 2017 |  BioCentury  |  Finance

LSP checks in

ImCheck Therapeutics S.A.S.’s focus on checkpoint receptors that are expressed on a subset of T cells that are different from the cellular targets of other checkpoint modulators convinced LSP to make its first immuno-oncology investment. The...
03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc.’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research plan...
19:39 , Dec 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection; fungal infection Mouse studies suggest CSF1 could help treat bacterial and fungal infections after hematopoietic stem cell and progenitor cell (HSPC) transplants. In a mouse model of HSPC transplant infected i.p. with lethal...
22:28 , Nov 2, 2016 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice haploinsufficient for TSHZ3 could model a subtype of autism involving renal tract defects. Sequencing studies in eight patients with autism, four of whom had renal tract abnormalities, identified overlapping genetic deletions...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Muscarinic acetylcholine receptor M1 (CHRM1; HM1); CHRM4 (HM4)

Neurology INDICATION: Parkinson's disease (PD) Mouse studies suggest antagonizing CHRM1 or CHRM4 could help treat PD. In a mouse model of PD, intrastriatal injection of the CHRM1 antagonist telenzepine or the CHRM4 antagonist tropicamide decreased sensorimotor and...
08:00 , Mar 5, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Amphiphilic dendrimer-based micelles for chemotherapy delivery

Drug delivery TECHNOLOGY: Nanoparticles Micelle nanoparticles formed from amphiphilic dendrimers could improve delivery of doxorubicin to cancer cells. Doxorubicin was mixed with self-assembling amphiphilic dendrimers composed of a hydrophilic polyamidoamine dendron linked with two hydrophobic C18 alkyl...
08:00 , Mar 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Low-density lipoprotein receptor (LDLR)

Cancer INDICATION: Pancreatic cancer In vitro, mouse and patient sample studies suggest inhibiting LDLR could help treat pancreatic ductal adenocarcinoma (PDAC). In primary human PDAC tumors, LDLR expression was associated with tumor recurrence and metastasis. In mouse...
08:00 , Jan 15, 2015 |  BC Innovations  |  Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...